The Effect of Bevacizumab on Corneal Neovascularization

Sponsor
Instituto de Olhos de Goiania
Study ID
NCT00797303
Phase
PHASE4
Status
Completed

Conditions

  • Corneal Neovascularization

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • Bevacizumab — DRUG
    subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months

Study Details

Eight patients with corneal neovascularization were treated with subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months. All patients had persistent corneal neovascularization for at least 6 months unresponsive to other treatments. Patients were monitored by ophthalmic exam and anterior segment photography.

Key Dates

First listed
Nov 25, 2008
Start date
Jan 31, 2006
Status verified
Nov 2011
Primary completion
Jul 31, 2008
Completion
Nov 30, 2008

Study Design

Enrollment
8 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 1
    A single intraoperative subconjunctival application of bevacizumab and 2 months follow-up

Primary Outcome Measure

The Effect of Bevacizumab on Corneal Neovascularization [ Time Frame: Compare the results ]

Related Studies